The Trump administration has opened a new front against transgender healthcare, and it is running through the billing office rather than the courtroom. The Department of Health and Human Services has released a report titled Wolves in White Coats, accusing hospitals of using incorrect diagnostic codes to bill insurers for pediatric gender-affirming care. Vice President JD Vance has referred roughly 150 healthcare organizations to the Department of Justice for criminal investigation.
The mechanism is unusual. The target is not.
What the administration is describing as fraud, providers have described openly for years as a workaround for insurance systems that historically refused to cover transgender care under its own name. That distinction — between a disputed coding practice and a criminal scheme — is where the entire fight now lives.
Consider how this reads to someone inside the system. Pediatric endocrinologists at large academic hospitals have spent years counseling families through puberty blockers and hormone therapy. Billing teams have, for most of that time, used endocrine and mental health codes that reflect what insurers would actually pay for. A referral to the DOJ does not distinguish these providers from someone running a Medicare kickback scheme. That is, in the view of critics, the point.
A review by the fact-checking outlet Important Context lays out the architecture. Two of the report’s ten listed authors — Victoria Coley, the Independent Women’s Forum’s senior vice president of communications, and Neeraja Deshpande, an IWF policy analyst — are on staff at the group, a right-wing advocacy organization; several other contributors are drawn from allied organizations like the Center for Christian Virtue and the Ethics and Public Policy Center. Only three of the ten authors are medical doctors, and just two work in a clinically relevant field. The document was not produced by an independent panel of medical experts. It was produced largely by activists and think-tank staff and given the imprimatur of the federal health agency, then handed to prosecutors.
Health policy advocates have called the report part of a broader pattern from this administration: using the power of government to attack science and target health care providers instead of helping families get the care they need. Legal advocates have described it more bluntly as an intimidation campaign.
The billing question at the center of the report is real, but it is not new, and it is not secret. A 2021 journal article described the code “endocrine disorder, unspecified” as one that, according to medical literature, some providers have used when billing for transgender care, which advocacy groups have noted may help patients avoid potential insurance discrimination or privacy concerns. Provider guidance documents have discussed the practice for years, framing it as a way to secure coverage from insurers who explicitly excluded transgender care from their policies.
Reasonable people can disagree about whether that practice constitutes creative coding or improper billing. What is harder to argue is that it was hidden.
The legal strategy behind the referral becomes clearer once the courtroom history is laid alongside it. Federal judges have quashed nearly every DOJ subpoena seeking the private records of transgender patients. Federal courts have ruled that subpoenas issued to healthcare providers appear designed to interfere with states’ rights to protect gender-affirming care within their borders and to harass and intimidate institutions to stop providing such care.
A fraud investigation reshapes that calculus. Subpoenas issued under a criminal fraud predicate are much harder for courts to block on harassment grounds, because the government can point to a specific alleged crime rather than a policy disagreement. The billing-fraud framing is, in effect, a key cut to fit a lock the administration has been unable to pick.
Three of the largest pediatric providers have already folded. Texas Children’s Hospital, the Cleveland Clinic Foundation, and, as of early August, Connecticut Children’s Medical Center have settled with the administration and agreed to stop providing gender-affirming treatments to minors entirely. None of the settlements included a finding of fraud or an admission of liability; Connecticut Children’s, for instance, denied all the allegations even as it agreed to the terms. The institutions chose the cost of ending a program over the cost of fighting.
For a hospital general counsel, that math is not mysterious. Healthcare attorneys who advise regional systems would recognize the pattern from any high-stakes federal investigation: the process itself is the penalty. Document production alone can be enormously costly. Reputational exposure begins the day the subpoena arrives, not the day a verdict lands.
This is where the intimidation critique gains its force. Even if not a single one of the 150 referrals results in a conviction — and many legal observers doubt they will — the referral itself changes provider behavior. Boards ask questions. Malpractice carriers reassess. Individual clinicians consider whether to keep seeing patients at all.
The medical evidence the report gestures at is thinner than the enforcement built on top of it. Medical literature indicates low regret rates among recipients of gender-affirming care. That does not settle every clinical question about adolescent care — there are genuine debates within the field about age thresholds, assessment protocols, and long-term outcomes — but it does not resemble the picture the report paints of a fraudulent industry preying on children.
The political ground has shifted underneath all of this. More than half of U.S. states have outlawed gender-affirming medical care for minors in the last few years. The January 2025 executive order laid the groundwork for a federal restriction to layer on top of state bans. The HHS report and the DOJ referrals complete a third layer: financial and criminal exposure aimed at the providers still operating in states where the care remains legal.
Case managers at community health centers see the downstream effect in their daily work. Families who traveled from restrictive states to receive care in states where it remains legal now ask whether their records could be pulled into a federal investigation. The answer, honestly given, is that courts have so far protected those records, but the ground keeps moving.
There is a broader institutional pattern here that runs beyond this specific issue. When direct regulation is blocked, enforcement migrates to adjacent authorities — brand risk, billing compliance, tax status, licensing. The healthcare system is particularly vulnerable to this kind of pressure because it runs on federal reimbursement and thin operating margins. A credible fraud allegation is enough to freeze a program even before a court weighs in.
The report also invites private lawsuits. By framing pediatric gender-affirming care as a fraudulent enterprise, it offers a template for plaintiffs’ attorneys and state attorneys general to pursue civil actions against providers, insurers, and pharmacies. Major pharmacy chains are among the entities named in the DOJ referral. The chilling effect on pharmacy networks is difficult to overstate; a national chain does not need to lose a case to decide the category is not worth the risk.
What the report does not do is present new medical evidence, new outcomes data, or an independent audit of billing practices at the 150 organizations named. What it does is repackage a long-documented coding workaround as a criminal scheme and hand federal prosecutors the paperwork.
Providers and their attorneys will argue in court that the billing codes reflect the reality of how insurance categorization has historically worked, not an intent to defraud. That argument may well succeed on the merits in individual cases. The question is how many programs survive long enough to make it.
For patients and families in the middle of care, the practical stakes are immediate. Access is narrowing not because the law has changed in their state, but because the institutions that provide the care are recalculating their exposure. That is what an intimidation strategy looks like when it works — the outcome arrives before the ruling.
The fight over transgender healthcare has moved from what the government can prohibit to what providers can be pressured into abandoning on their own. The billing code was never the real subject. It was the instrument closest to hand.